[CALA] Calithera Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.5 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CALA

Refresh chart

Strongest Trends Summary For CALA

CALA is in the long-term down -55% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-8.67
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.57% ROE-21.41% ROI
Current Ratio25.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-20.47 M Cash From Operating Activities-7.63 M Gross Profit
Net Profit-7.86 M Operating Profit-7.87 M Total Assets96.87 M Total Current Assets90.31 M
Total Current Liabilities3.52 M Total Debt Total Liabilities3.77 M Total Revenue
Technical Data
High 52 week9.05 Low 52 week4.08 Last close5.64 Last change-1.4%
RSI34 Average true range0.32 Beta1.56 Volume180.6 K
Simple moving average 20 days-6.72% Simple moving average 50 days-10.43% Simple moving average 200 days1.68%
Performance Data
Performance Week-6.93% Performance Month-7.54% Performance Quart5.22% Performance Half7.43%
Performance Year-32.46% Performance Year-to-date25.33% Volatility daily2.73% Volatility weekly6.09%
Volatility monthly12.49% Volatility yearly43.26% Relative Volume2060.39% Average Volume172.05 K
New High New Low

News

2019-08-28 08:00:00 | Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?

2019-08-10 09:57:34 | Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-08 16:05:00 | Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

2019-08-01 07:07:00 | Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-07-24 10:40:51 | Does Calithera Biosciences, Inc. NASDAQ:CALA Have A High Beta?

2019-07-02 08:00:00 | Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib

2019-06-27 19:15:02 | Calithera Biosciences Inc CALA PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares

2019-06-21 16:04:00 | Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

2019-06-18 23:00:00 | Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock

2019-06-18 13:16:37 | Did You Miss Calithera Biosciences's NASDAQ:CALA 37% Share Price Gain?

2019-06-17 16:01:00 | Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

2019-06-17 10:08:24 | Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more

2019-06-17 10:04:42 | Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy

2019-06-17 06:00:00 | Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

2019-05-14 12:34:47 | Calithera Biosciences, Inc. CALA Q1 2019 Earnings Call Transcript

2019-05-10 18:08:28 | Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-10 05:14:17 | Calithera: 1Q Earnings Snapshot

2019-05-09 16:06:00 | Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights 

2019-05-02 10:32:02 | Analysts Estimate Calithera CALA to Report a Decline in Earnings: What to Look Out for

2019-04-25 07:34:54 | How Many Calithera Biosciences, Inc. NASDAQ:CALA Shares Do Institutions Own?

2019-04-02 07:05:00 | Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019

2019-03-27 17:39:09 | Calithera CALA Initiates Phase I/II Study of Telaglenastat

2019-03-26 07:05:00 | Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

2019-03-07 20:40:17 | Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 16:06:00 | Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

2019-03-05 07:05:00 | Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

2019-03-04 07:05:00 | Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

2019-02-27 16:35:00 | Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019

2019-02-22 08:00:00 | Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-21 16:05:00 | Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

2019-02-16 06:00:00 | Updated Results from Phase 1 Study of Telaglenastat CB-839 to be Presented at 2019 ASCO Genitourinary Cancer Symposium

2019-02-04 07:05:00 | Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat CB-839 and Everolimus in Renal Cell Carcinoma

2019-01-28 07:30:00 | Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-18 14:19:35 | What Did Calithera Biosciences, Inc.’s NASDAQ:CALA CEO Take Home Last Year?

2019-01-07 07:05:00 | Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline

2018-11-30 08:00:00 | Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference

2018-11-21 09:50:06 | Intrinsic Calculation For Calithera Biosciences Inc NASDAQ:CALA Shows Investors Are Overpaying

2018-11-09 08:10:00 | New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production

2018-11-08 07:11:14 | Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT

2018-11-07 20:35:01 | Calithera CALA Reports Q3 Loss, Lags Revenue Estimates

2018-11-07 19:32:17 | Calithera: 3Q Earnings Snapshot

2018-11-07 16:05:00 | Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-10-31 08:00:00 | Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

2018-10-15 08:55:00 | Market Trends Toward New Normal in Nasdaq, Calithera Biosciences, Pinnacle West Capital, National Instruments, American Vanguard, and American Axle & Manufacturing — Emerging Consolidated Expectations, Analyst Ratings

2018-10-05 13:06:47 | What Investors Should Know About Calithera Biosciences Inc’s NASDAQ:CALA Financial Strength

2018-10-05 07:01:00 | Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

2018-10-05 07:00:00 | Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® palbociclib and talazoparib in Combination with CB-839

2018-09-26 08:00:00 | Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

2018-09-24 08:00:00 | Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable